

ATRIAL FIBRILLATION AND OBESITY:
CHARACTERIZATION OF ELECTRO-STRUCTURAL ATRIAL
SUBSTRATE WITH SUSTAINED OBESITY AND REVERSAL
UPON WEIGHT REDUCTION

Rajiv Mahajan MBBS, MD, FRACP

Department of Cardiology

Royal Adelaide Hospital

and

Discipline of Medicine

University of Adelaide

A thesis submitted to the University of Adelaide

in fulfillment of the requirements for the degree of

Doctor of Philosophy

February 2014

To my parents Sabita and Bal,

my soulmate Kavita

and

my daughter Idhika

Table of contents

Abstract.....	XVII
Declaration.....	XX
Acknowledgements.....	XXII
Publications and Communications to Learned Societies.....	XXIV
Prizes and Awards during Candidature	XXVII
Chapter 1.....	1
Literature Review.....	1
1.1 Atrial Fibrillation: background.....	1
1.2 Electrophysiological basis of AF	2
1.2.1 Mechanisms of AF	3
1.2.2 Left atrial dominance in AF.....	4
1.2.3 Importance of atrial foci in AF.....	5
1.2.4 Substrate and triggers in the genesis of AF	6
1.3 Atrial remodeling and AF	7
1.3.1 Atrial tachycardia remodeling model.....	7
1.3.1.1 Alteration in ion channel in atrial tachycardia remodeling.....	8
1.3.1.2 Long term atrial tachycardia remodeling causes structural changes	9
1.3.2 Atrial structural remodeling model.....	10

1.4 Structural remodeling in common clinical substrates	11
1.4.1 Age	11
1.4.2 Hypertension	12
1.4.3 Congestive heart failure	13
1.4.4 Mitral valve disease	15
1.4.5 Atrial septal defect	16
1.4.6 Coronary artery disease	16
1.4.7 Obstructive sleep apnoea.....	17
1.4.8 Obesity.....	19
1.5 Histological abnormalities with atrial structural remodeling.....	19
1.5.1 Atrial fibrosis.....	19
1.5.2 Myocyte hypertrophy.....	20
1.5.3 Atrial architecture.....	20
1.5.4 Connexin expression and AF	21
1.6 Atrial fibrosis and signal transduction alterations in atrial structural remodeling	22
1.6.1 Transforming growth factor β	23
1.6.2 Angiotensin II.....	24
1.6.3 Endothelin-1	25
1.6.4 Connective tissue growth factor	26
1.6.5 Platelet derived growth factor	26

1.6.6 Oxidative stress and Inflammation.....	27
1.6.7 Matrix metalloproteinase proteins (MMP) and tissue inhibitor of MMP (TIMP)	29
1.7 Obesity	30
1.7.1 Obesity and Atrial Fibrillation- the epidemiologic link.....	30
1.7.2 Obesity mediators of Atrial Fibrillation	31
1.7.2.1 Left atrial enlargement and diastolic dysfunction	32
1.7.2.2 Inflammatory milieu	32
1.7.2.3 Direct Lipotoxicity.....	32
1.7.2.4 Obstructive sleep apnea.....	33
1.7.3 Electrical remodeling in obesity	33
1.7.4 Pericardial fat and Atrial Fibrillation	33
1.7.5 Weight reduction and risk of atrial fibrillation.....	35
Figure 1 Signaling pathways in fibrosis	38
Chapter 2.....	39
Electrophysiological, electroanatomical and structural remodeling of the atria as a consequence of sustained obesity.....	39
2.1 Introduction	39
2.2 Methods	40
2.2.1 Obese Ovine Model	40
2.2.2 Control Group.....	41

2.2.3 Study Preparation.....	41
2.2.4 Body Composition	41
2.2.5 Transthoracic echocardiography.....	41
2.2.6 Hemodynamic assessment.....	42
2.2.7 Electrophysiological study.....	42
2.2.8 Electroanatomical mapping.....	43
2.2.9 Effective Refractory Period.....	44
2.2.10 Atrial conduction velocity.....	44
2.2.11 Atrial voltage	45
2.2.12 AF vulnerability and duration.....	45
2.2.13 Histological assessment.....	45
2.3 Statistical Analysis	47
2.4 Results	48
2.4.1 Group characteristics.....	48
2.4.2 Structural and hemodynamic remodeling.....	48
2.4.3 Electroanatomic remodeling.....	49
2.4.4 Atrial refractoriness.....	49
2.4.5 Conduction velocity.....	49
2.4.6 Complex fractionation	50
2.4.7 Voltage.....	50

2.4.8 Vulnerability for atrial fibrillation.....	51
2.4.9 Atrial musculature infiltration by epicardial adipose tissue	51
2.4.10 Fibrosis.....	52
2.4.11 Atrial TGFβ1 protein	52
2.5 Discussion.....	52
2.5.1 Major Findings	52
2.5.2 Atrial substrate in AF	53
2.5.3 AF substrate in Obesity.....	54
2.5.3.1 Electroanatomic remodeling with Obesity.....	54
2.5.3.2 Atrial fibrosis and atrial TGFβ1 with sustained obesity.....	55
2.5.4 Pericardial fat and AF	56
2.5.5 Study limitations.....	57
2.5.6 Conclusion	57
Table 1: Structural and hemodynamic characteristics of the control and obese groups.....	58
Table 2: Electrophysiology and structural characteristics of the control and obese groups.....	59
Figure 1: Distribution of ERP in obese and control groups at two cycle lengths....	60
Figure 2: Conduction velocity slowing and increased conduction heterogeneity with obesity	61

Figure 3: Changes in mean endocardial voltage and voltage heterogeneity with obesity	62
Figure 4: Atrial fibrillation vulnerability in the obese and control groups.....	63
Figure 5 Distribution of epicardial fat and infiltration of atrial myocardium by contiguous epicardial fat	64
Figure 6: Atrial fibrosis and atrial TGF β 1 expression with obesity.....	65
Chapter 3.....	66
Atrial fibrillation and obesity: Reversibility of atrial substrate with weight reduction..	66
3.1 Introduction	66
3.2 Methods	67
3.2.1 Study Groups	67
3.2.2 Obese Ovine Model	67
3.2.3 Study Protocol	68
3.2.4 Body Composition	68
3.2.5 Transthoracic echocardiography.....	69
3.2.6 Cardiac Magnetic Resonance	69
3.2.7 Electrophysiological study.....	69
3.2.7.1 Atrial conduction	70
3.2.7.2 Heterogeneity of conduction (CHI)	70
3.2.7.3 Atrial effective refractory period.....	70
3.2.7.4 AF vulnerability.....	71

3.2.8 Hemodynamic assessment	71
3.2.9 Histological assessment.....	71
3.2.9.1 Inflammation	71
3.2.9.2 Fibrosis assessment	72
3.2.9.3 Connexin43 expression	72
3.2.10 Western blot.....	73
3.3 Statistical Analysis	74
3.4 Results	76
3.4.1 Hemodynamic and imaging characteristics.....	76
3.4.2 Electrophysiological remodeling	76
3.4.2.1 Conduction velocity.....	77
3.4.2.2 Conduction heterogeneity Index (CHI):.....	77
3.4.2.3 Atrial refractoriness.....	77
3.4.2.4 Vulnerability for atrial fibrillation.....	78
3.4.3 Structural and molecular remodeling	78
3.4.3.1 Inflammation	78
3.4.3.2 Fibrosis.....	78
3.4.3.3 Atrial TGF β 1 protein expression.....	79
3.4.3.4 Atrial Endothelin-1 and ER-A and B receptor expression.....	79
3.4.3.5 Connexin43 expression	80

3.5 Discussion.....	80
3.5.1 Major Findings.....	80
3.5.2 AF substrate in Obesity.....	81
3.5.3 Electrophysiological remodeling in sustained obesity.....	82
3.5.4 Determinants of atrial fibrosis in obesity.....	82
3.5.5 Reversal of obesity related AF substrate with weight reduction.....	83
3.6 Limitations.....	85
3.7 Clinical Implications.....	85
Table 1: Body mass, structural, hemodynamic and electrophysiological and molecular characteristics of obese, weight loss and control groups.....	86
Figure1: Study Outline.....	88
Figure 2: Representative activation maps (panel I) and corresponding phase histograms (panel II) of left atrium (300ms cycle length) in control, obese, 15- and 30% weight reduction groups.....	89
Figure 3: I) ERP distribution II) Conduction velocity and III) Conduction heterogeneity in control, obese, 15- and 30% weight loss groups.....	90
Figure 4: Inflammation, fibrosis and connexin expression with weight loss.....	91
Figure 5: Atrial TGF β 1 and Endothelin, ER-A and B expression with weight reduction.....	92
Chapter 4.....	93

Obesity and Weight Reduction: Impact on the endocardial substrate for Atrial Fibrillation	93
4.1 Introduction	93
4.2 Methods	94
4.2.1 Study Groups	94
4.2.2 Obese Ovine Model	94
4.2.3 DEXA scan	95
4.2.4 Transthoracic echocardiography	95
4.2.5 Electrophysiological study	95
4.2.5.1 Electroanatomical mapping	96
4.2.5.2 Atrial conduction velocity	97
4.2.5.3 Atrial voltage	98
4.2.5.4 Effective Refractory Period	98
4.2.5.5 AF inducibility and duration	99
4.2.6 Hemodynamic assessment	99
4.3 Statistical Analysis	99
4.4 Results	100
4.4.1 Group characteristics	100
4.4.2 Body mass Characteristics	100
4.4.3 Structural and hemodynamic remodeling	100
4.4.4 Electroanatomic remodeling	101

4.4.4.1 Conduction velocity	101
4.4.4.2 Complex fractionation	101
4.4.4.3 Voltage.....	102
4.4.4.4 Atrial refractoriness.....	102
4.4.4.5 Vulnerability for atrial fibrillation.....	102
4.5 Discussion	103
4.5.1 Major Findings	103
4.5.2 Substrate for AF in Obesity.....	103
4.5.3 Mechanism of AF in obesity	104
4.5.4 Reversal of the substrate for AF due to obesity.....	105
4.6 Limitations.....	106
4.7 Clinical Implications.....	106
4.8 Conclusion	107
Table 1: Body mass, structural, hemodynamic and electrophysiological characteristics of Obese- pre and post weight loss and Control groups	108
Figure 1: Study outline.....	110
Figure 2: Endocardial conduction velocity and heterogeneity with weight reduction	111
Figure 3: Representative bipolar voltage map of the left atrium in sinus rhythm in control and obese group- pre and post weight loss.....	112

Figure 4: ERP distribution in Obese-pre and post weight loss and Control groups.	113
Chapter 5.....	114
Cardiovascular Magnetic Resonance imaging of total and atrial pericardial adipose tissue: A validation study and development of a three dimensional pericardial adipose tissue model.....	114
5.1 Introduction	114
5.2 Methods	115
5.2.1 Definitions	115
5.2.2 Cardiovascular Magnetic Resonance Protocol and Analysis.....	116
5.2.3 Pericardial fat quantification at Autopsy.....	117
5.3 Statistical Analysis	118
5.4 Results	118
5.4.1 Autopsy pericardial adipose tissue regional distribution.....	119
5.4.2 Agreement of CMR assessment with Autopsy measures of pericardial adipose tissue	119
5.4.3 Intra- and inter-observer reliability of CMR assessment of pericardial adipose tissue.....	119
5.5 Discussion.....	121
5.6 Limitations.....	123
5.7 Clinical Implications.....	123

5.8 Conclusion	124
Table 1: Pericardial adipose tissue (PAT) mass as assessed on Autopsy and CMR	125
Table 2: Intra-observer reproducibility of CMR measures of pericardial adipose tissue (PAT)	126
Table 3: Inter-observer reproducibility of CMR measures of pericardial adipose tissue (PAT)	127
Figure 1: Three dimensional model of pericardial adipose tissue using semi- automated in-house software.....	128
Figure 2: The process of atrial and ventricular pericardial adipose tissue measurement via autopsy.....	129
Figure 3: Agreement of CMR assessment with autopsy measures of pericardial adipose tissue	130
Chapter 6.....	131
Epicardial fat depots and atrial remodeling in obese patients with atrial fibrillation: evidence for a direct impact	131
6.1 Introduction	131
6.2 Methods	132
6.2.1 MRI Protocol and Analysis.....	134
6.2.2 Electrophysiology Study	135
6.3 Statistical Analysis	137
6.4 Results	138

6.4.1 Group characteristics.....	138
6.4.2 Epicardial fat measures of adiposity	138
6.4.3 Electrophysiological remodeling with obesity	139
6.4.3.1 Conduction Velocity	139
6.4.3.2 Fractionation	139
6.4.3.3 Left atrial voltage.....	139
6.4.3.1.1 <i>Regional differences:</i>	139
6.4.4 Correlation of pericardial fat measures with electrophysiological parameters	140
6.5 Discussion.....	141
6.5.1 Major findings.....	141
6.5.2 Association of obesity, pericardial fat and AF.....	142
6.5.3 Electroanatomic remodeling with obesity	143
6.5.4 Potential mechanistic role of pericardial fat	145
6.6 Limitations.....	146
6.7 Clinical implications and future directions.....	146
6.8 Conclusion	147
Table 1: Patient characteristics of the obese and control groups	148
Table 2: Regional electroanatomic remodeling with obesity	149
Figure 1: Pericardial fat representations of left atrial, total atrial and ventricular epicardial fat depots.....	150

Figure 2: Representative left atrial voltage maps of the control and obese group
..... 151

Chapter 7..... 152

Conclusion and future directions..... 152

Chapter 8..... 156

References 156

Abstract

Atrial fibrillation (AF) is the most prevalent arrhythmia affecting humans. The identification of risk factors for AF has ushered a risk factor based approach for management. Obesity is a highly prevalent and novel risk factor for AF with a potential for reversibility. The epidemiological link between obesity and AF has been established in population based studies; however the atrial substrate remains to be fully characterized. Furthermore, mechanism and degree of reversibility with weight reduction has not been described. This thesis evaluates the various aspects of endocardial and epicardial atrial remodeling with sustained obesity and the underlying mechanisms in an ovine model. It also examines the endocardial atrial remodeling with obesity in humans and its relationship with epicardial adipose tissue. In addition, the reversal of obesity related atrial substrate with weight reduction has been characterized in a sustained obesity ovine model.

Chapter 2 examines the endocardial electrophysiological remodeling with sustained obesity in an ovine model. Sustained obesity was associated bi-atrial slow and heterogeneous atrial conduction with increased fractionation and greater vulnerability for AF. There is no significant alteration in endocardial atrial refractoriness. Although there was no difference in mean voltage there was increased voltage heterogeneity. Obesity was associated with overexpression of pro-fibrotic TGF β 1 and increased atrial fibrosis. Infiltration of the epicardial atrial musculature by the contiguous fat was seen and this could represent a unique substrate for AF in obesity.

Chapter 3 describes the reversal of the obesity related atrial substrate with weight reduction in an ovine model. Sustained obesity was associated with bi-atrial epicardial slow and heterogeneous conduction, reduced atrial refractoriness (epicardial) and increased propensity for AF. This was associated with hemodynamic stress and diastolic dysfunction. Histologically obesity was associated with atrial fibrosis, inflammation and fatty infiltration. There was up-regulation of atrial TGF β 1 expression and Endothelin receptor B. The TGF β 1 expression correlated with electrophysiological changes and atrial fibrosis, and this relationship persisted even after adjusting for left atrial pressure. There was decreased expression of atrial gap junction protein Connexin43 expression. The changes observed with sustained obesity were reversed with moderate weight reduction.

Chapter 4 describes the electrophysiological reverse remodeling with weight reduction in an ovine model. Weight reduction resulted in improvement in endocardial atrial conduction velocity and decrease in conduction heterogeneity. However, the atrial refractoriness from endocardial sites did not change with either obesity or weight reduction. This is in contrast to epicardial atrial refractoriness which shortened with sustained obesity and improved to control values with weight reduction. This endocardial- epicardial dissociation in atrial refractoriness may represent part of the unique substrate for AF in obesity.

Chapter 5 describes the validation of atrial pericardial fat assessment on cardiac magnetic resonance imaging against the gold standard of autopsy.

Chapter 6 describes the electroanatomic remodeling with obesity in humans and describes the association with atrial pericardial fat.

NOTE: Pagination of the digital copy does not correspond with
the pagination of the print copy

Declaration

I certify that this work contains no material which has been accepted for the award of any other degree or diploma in my name, in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission in my name, for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint-award of this degree.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

The author acknowledges that copyright of published works contained within this thesis resides with the copyright holder(s) of those works. I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library Search and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Rajiv Mahajan
February 2014

Acknowledgements

I would like to thank Professor Prashanthan Sanders, my primary supervisor, for his mentorship and support during my doctoral training. I am particularly encouraged by his enthusiasm, originality of ideas, and the drive to lead projects successfully to completion. He has demonstrated the fine art in balancing a successful career as a clinician, scientist, teacher and a family person. I am also thankful to my co-supervisors, Prof Joseph Selva, Dr Anthony Brooks and Dr Pawel Kuklik for their guidance. I am grateful for the scholarship support from the University of Adelaide (Australian Post Graduate Award, Leo J Mahar Scholarship).

I cherish my clinical electrophysiology training at The Royal Adelaide Hospital with Prof Prashanthan Sanders, Drs Glenn Young and Kurt Roberts-Thomson. I also enjoyed working alongside co-fellows: Drs Dennis Lau, Muayad Alasady, Han Lim, Anand Ganesan, Rajeev Pathak and Darragh Twomey. I would like to convey special thanks to Drs Dennis Lau and Muayad Alasady for their guidance and support at difficult times during this incredible journey. Support from the following was also crucial: Drs Nicholas Shipp, John Wood, Jim Manavis, Chrisan Samuel, Shiv Thaigaimani, Melissa Middeldorp and Aimie Paukner. All these individuals contributed to a very productive & successful research environment. I am also thankful to the contribution made by Adam Nelson and Christopher Wong and the support from Loren Mathews and Dr Tim Kuchel at LARIF.

In particular, I am blessed by the understanding and unwavering support from my beloved wife, Kavita and our beautiful daughter Idhika who have walked every step with me in my pursuit of academia. I am also blessed to have the support and

blessings of our parents and siblings who have shared my tribulations and joys during this journey. Above all, I thank our great God for being so kind.

Publications and Communications to Learned Societies

Chapter 2

1. **Presentation:** Presented at the Annual Scientific Sessions of the Heart Rhythm Society, May 2013, Denver, USA and published in abstract form (Heart Rhythm 2013;10: S259).
2. **Presentation:** Presented at the Annual Scientific Sessions of the Heart Rhythm Society, May 2012, Boston, USA and published in abstract form (Heart Rhythm 2012; 9: S185).
3. **Presentation:** Presented at the Annual Scientific Sessions of Cardiology Society of Australia, August 2012, Brisbane, Australia and published in abstract form New Zealand (Heart, Lung and Circulation 2012; 21;S125)

Chapter 3

1. **Young Investigator Award Presentation:** Presented at the Annual Scientific Sessions of the Heart Rhythm Society, May 2013, Denver, USA and published in abstract form (Heart Rhythm 2013; 10: S484).
2. **Young Investigator Award, Ralph Reader prize Presentation:** Presented at the Annual Scientific Sessions of Cardiology Society of Australia and New Zealand, August 2013, Goldcoast, Australia and published in abstract form (Heart, Lung and Circulation 2013; 22:S1-2)
3. **Best Oral Abstract Presentation:** Presented at the Annual Scientific Sessions of the Asia Pacific Heart Rhythm Society, October 2013, Hong

Kong, Hong Kong and published in abstract form (Journal of Arrhythmia 2013; 29:i1-130)

Chapter 4

1. **Presentation:** Presented at the Annual Scientific Sessions of Cardiology Society of Australia, August 2012, Brisbane, Australia and published in abstract form New Zealand (Heart, Lung and Circulation 2012; 21;S109-110)
2. **Presentation:** Presented at the Annual Scientific Sessions of the Heart Rhythm Society, May 2012, Boston, USA and published in abstract form (Heart Rhythm 2012; 9: S405).

Chapter 5

1. **Manuscript:** Mahajan R, Kuklik P, Grover S, Brooks AG, Sanders P, Selvanayagam JB. Cardiovascular magnetic resonance of total and atrial pericardial adipose tissue: A validation study and development of a 3 dimensional pericardial adipose tissue model. Journal of Cardiovascular Magnetic Resonance. 2013;15;73
2. **Presentation:** Presented at the Annual Scientific Sessions of Cardiology Society of Australia, August 2012, Brisbane, Australia and published in abstract form New Zealand (Heart, Lung and Circulation 2012; 21;S233)
3. **Presentation:** Presented at the Annual Scientific Sessions of the Heart Rhythm Society, May 2012, Boston, USA and published in abstract form (Heart Rhythm 2012; 9: S413).

Prizes and Awards during Candidature

1. Best Oral Abstract (First prize), Asia Pacific Heart Rhythm Society, 2013.
2. Ralph Reader Young Investigator Award (First prize), Cardiology Society of Australia and New Zealand, 2013.
3. Young Investigator Award (First prize), Heart Rhythm Society, Denver, 2013.
4. SA Heart Research Award (First prize), Adelaide Australia, 2013.
5. Cardiac Society of Australia and New Zealand Travelling Fellowship: 2013
6. First prize, Nimmo Prize, Royal Adelaide Hospital Research Forum, Adelaide Australia, 2012.
7. International Postgraduate Research Scholarship (2011). *University of Adelaide.*
8. Australian Post Graduate Award (2011). *University of Adelaide.*
9. Leo J Mahar Electrophysiology Scholarship (2011). *University of Adelaide.*